Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?

Merck shares fell 7.2% in a month after rising roughly 60% over the prior year, while the article characterizes the pullback as a correction despite significant risks. Keytruda generates more than 55% of pharmaceutical sales and is forecast to reach $35 billion in peak sales by 2028, but faces expected biosimilar competition around 2028–2029; Gardasil sales fell 9% in the first half of 2026. Merck’s phase III pipeline has nearly tripled since 2021 and the company sees more than $70 billion in non-risk-adjusted pipeline opportunity by the mid-2030s, though 2026 and 2027 earnings estimates have declined and the stock is rated Zacks #3 (Hold).

Analysis

MRK’s risk is a timing mismatch: the market is valuing a post-Keytruda portfolio before replacement assets have demonstrated comparable, durable cash generation. The pipeline’s stated commercial opportunity is non-risk-adjusted and spans years; it should not be treated as a revenue bridge. Meanwhile, acquisition costs and pressure in vaccines and legacy drugs can weaken near-term earnings even if the long-run portfolio improves. That creates scope for multiple compression if estimates keep drifting lower, despite continued Keytruda growth.

Keytruda Qlex may help retain patients and improve treatment convenience, but it does not by itself remove molecule-level biosimilar exposure. Gardasil’s China weakness also looks partly structural: lower-cost domestic supply raises the risk that resumed shipments do not restore prior demand. The melanoma vaccine result improves the value of the MRK–MRNA partnership, but without full efficacy, safety, and commercial-sharing details, it is not yet a basis for underwriting a material earnings offset. Similar caution applies to acquired pipeline assets: deal additions are not equivalent to de-risked launches.

Near term (days to weeks), the 7% pullback after strong performance is not clearly a valuation reset; the stock remains above its historical multiple, while published earnings estimates have moved down. Over 1–3 months, watch guidance and launch uptake for new products, Gardasil trends, and partnership data. Over 6–18 months, the central question is whether launches can build meaningful revenue before the 2028–29 exclusivity transition. A sharper-than-expected Keytruda erosion or failure to stabilize estimates would undermine the replacement thesis; sustained new-product growth and estimate revisions turning positive would falsify the cautious view.

Key Decisions for Investors

• Do not chase the dip in MRK yet; keep exposure at benchmark or modestly below until earnings revisions stabilize and new-product growth is visible in reported results. The upside is continued Keytruda-led cash generation; the downside is further multiple compression as the patent transition approaches.
• For existing MRK exposure, consider a partial hedge rather than an outright short: the patent cliff is important but not imminent, and near-term Keytruda momentum can support the shares. Reassess if guidance or Keytruda sales trends weaken materially.
• Treat MRNA as a catalyst watch, not a read-through trade: verify complete Phase III results, safety, regulatory timing, and the economics of the collaboration before assigning meaningful value to the vaccine program.
• Track quarterly Gardasil demand and inventory normalization in China, alongside MRK’s acquisition-related costs and new-product contribution. Persistent weakness or continued downward estimate revisions would argue for reducing exposure; improving trends would support reconsidering the dip.